| # | Title | Journal | Year | Citations |
|---|
| 1 | Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer | Gut and Liver | 2012 | 801 |
| 2 | Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region | Gut and Liver | 2016 | 399 |
| 3 | 25 Years of Proton Pump Inhibitors: A Comprehensive Review | Gut and Liver | 2017 | 371 |
| 4 | Cholangiocarcinoma: Current Knowledge and New Developments | Gut and Liver | 2017 | 361 |
| 5 | NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications | Gut and Liver | 2012 | 334 |
| 6 | 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma | Gut and Liver | 2019 | 255 |
| 7 | Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity | Gut and Liver | 2012 | 250 |
| 8 | Clostridium difficileInfection: A Worldwide Disease | Gut and Liver | 2014 | 247 |
| 9 | Diagnosis and Management of High Risk Group for Gastric Cancer | Gut and Liver | 2015 | 219 |
| 10 | The Miss Rate for Colorectal Adenoma Determined by Quality-Adjusted, Back-to-Back Colonoscopies | Gut and Liver | 2012 | 174 |
| 11 | Bile Acid Diarrhea: Prevalence, Pathogenesis, and Therapy | Gut and Liver | 2015 | 171 |
| 12 | 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma | Gut and Liver | 2015 | 167 |
| 13 | Pathophysiology and Management of Alcoholic Liver Disease: Update 2016 | Gut and Liver | 2017 | 167 |
| 14 | Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study | Gut and Liver | 2009 | 153 |
| 15 | Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions | Gut and Liver | 2015 | 150 |
| 16 | Population Screening for Colorectal Cancer Means Getting FIT: The Past, Present, and Future of Colorectal Cancer Screening Using the Fecal Immunochemical Test for Hemoglobin (FIT) | Gut and Liver | 2014 | 148 |
| 17 | Current Trends in the Management of Gastroesophageal Reflux Disease | Gut and Liver | 2018 | 147 |
| 18 | Dietary Factors: Major Regulators of the Gut's Microbiota | Gut and Liver | 2012 | 146 |
| 19 | Immune Response and the Tumor Microenvironment: How They Communicate to Regulate Gastric Cancer | Gut and Liver | 2014 | 143 |
| 20 | Drug-Induced Liver Injury: Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multiflorum Thunb | Gut and Liver | 2011 | 139 |
| 21 | Irreversible Electroporation: A Novel Image-Guided Cancer Therapy | Gut and Liver | 2010 | 139 |
| 22 | Overview of Deep Learning in Gastrointestinal Endoscopy | Gut and Liver | 2019 | 132 |
| 23 | Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy | Gut and Liver | 2017 | 126 |
| 24 | Anxiety, Depression and Quality of Life in Patients with Irritable Bowel Syndrome | Gut and Liver | 2011 | 124 |
| 25 | Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions | Gut and Liver | 2016 | 124 |
| 26 | Biliary Strictures after Liver Transplantation | Gut and Liver | 2011 | 123 |
| 27 | Clinical Significance of Hiatal Hernia | Gut and Liver | 2011 | 119 |
| 28 | Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial | Gut and Liver | 2018 | 116 |
| 29 | Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome | Gut and Liver | 2015 | 114 |
| 30 | Diverticular Disease: An Update on Pathogenesis and Management | Gut and Liver | 2018 | 112 |
| 31 | Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics | Gut and Liver | 2017 | 111 |
| 32 | Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features | Gut and Liver | 2018 | 106 |
| 33 | RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention | Gut and Liver | 2019 | 106 |
| 34 | Current and Emerging Biologics for Ulcerative Colitis | Gut and Liver | 2015 | 103 |
| 35 | Red Cell Distribution Width: A Novel Marker of Activity in Infl ammatory Bowel Disease | Gut and Liver | 2011 | 101 |
| 36 | Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer | Gut and Liver | 2013 | 98 |
| 37 | Cellular and Molecular Basis of Intestinal Barrier Dysfunction in the Irritable Bowel Syndrome | Gut and Liver | 2012 | 95 |
| 38 | Cerulein Pancreatitis: Oxidative Stress, Inflammation, and Apoptosis | Gut and Liver | 2008 | 91 |
| 39 | Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease | Gut and Liver | 2019 | 90 |
| 40 | The Pathogenesis and Management of Achalasia: Current Status and Future Directions | Gut and Liver | 2015 | 88 |
| 41 | Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase inMethanobrevibacter smithii, Which Is Associated with Higher Methane Production | Gut and Liver | 2016 | 88 |
| 42 | Generation of Multilayered 3D Structures of HepG2 Cells Using a Bio-printing Technique | Gut and Liver | 2017 | 88 |
| 43 | The Role of Bacteria in the Pathogenesis of Inflammatory Bowel Disease | Gut and Liver | 2010 | 86 |
| 44 | Biliary Stricture after Adult Right-Lobe Living-Donor Liver Transplantation with Duct-to-Duct Anastomosis: Long-Term Outcome and Its Related Factors after Endoscopic Treatment | Gut and Liver | 2010 | 86 |
| 45 | Functional Dyspepsia: Advances in Diagnosis and Therapy | Gut and Liver | 2017 | 85 |
| 46 | Prevalence and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia: A Nationwide Multicenter Prospective Study in Korea | Gut and Liver | 2013 | 84 |
| 47 | Management Strategies for Gallbladder Polyps: Is It Possible to Predict Malignant Gallbladder Polyps? | Gut and Liver | 2008 | 83 |
| 48 | Efficacy of Current Traction Techniques for Endoscopic Submucosal Dissection | Gut and Liver | 2020 | 81 |
| 49 | Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics | Gut and Liver | 2010 | 80 |
| 50 | Radiofrequency Ablation of Hepatocellular Carcinoma: Pros and Cons | Gut and Liver | 2010 | 78 |
